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New WHO odontogenic tumor 
classification: impact on prevalence in 
a population
Objectives: This study approaches the history of reclassifications and 
redefinitions around the odontogenic keratocyst (OK), as proposed by the 
World Health Organization (WHO), and aims to understand the impact of 
those changes on the prevalence and epidemiology of odontogenic tumors 
(OTs). Methodology: Cases of OTs diagnosed in an Oral Pathology service 
between January 1996 and December 2016 were reviewed. Demographic 
data of patients such as age, gender and site of lesions were retrieved from 
their respective records. Results: Within the studied period, 7,805 microscopic 
reports were elaborated and 200 (2.56%) of these were diagnosed as OTs. Out 
of these 200, between 1996 and 2005, prior to the 2005 WHO classification, 
there were 41 (20.5%) OTs cases, being odontoma the most frequent (23; 
56.09%), followed by ameloblastoma (8; 19.51%) and myxoma (03; 7.31%). 
Between 2006 and 2016, after the previous 2005 WHO classification there 
were 159 (79.5%) OTs, being odontogenic keratocystic tumor (KCOT) the 
most frequent (68; 42.76%), followed by odontoma (39; 24.52%) and 
ameloblastoma (21; 13.20%). Conclusions: As of today, the most recent WHO 
classification to be followed brings KCOT back to the cyst category, which 
will  impact on the prevalence and epidemiology of OTs; thus, this study was 
able to identify a considerable increase (287.80%) in the prevalence of OTs 
when the 2005 WHO classification was utilized. Despite being an important 
academic exercise, classifying odontogenic lesions and determining whether 
to place the odontogenic keratocyst in a cyst or tumor category is crucial 
to establish the correct diagnosis and treatment to follow, whether by oral 
medicine or oral surgery specialist, or by the general practitioner. 
Keywords: Oral pathology. Odontogenic tumors. Biopsy. Neoplasia
Bianca Caroline Figueiredo BIANCO1
Felipe Fornias SPERANDIO1
João Adolfo Costa HANEMANN2
Alessandro Antônio Costa PEREIRA¹
Original Article
http://dx.doi.org/10.1590/1678-7757-2019-0067
1Universidade Federal de Alfenas, Instituto de Ciências Biomédicas, Departamento de Patologia e 
Parasitologia. Alfenas, MG, Brasil. 
²Universidade Federal de Alfenas, Faculdade de Odontologia, Departamento de Clínica e Cirurgia, 
Alfenas, MG, Brazil.
Corresponding address:
Bianca Caroline Figueiredo Bianco
Rua: Baptista Formaggio, 213 - Dois Córregos - 
13420-834 - Piracicaba - SP - Brasil.13420-834
e-mail: biancabianco_2006@hotmail.com
2020;28:e201900671/6
J Appl Oral Sci. 2020;28:e201900672/6
Introduction
The first consensus about odontogenic tumors 
(OTs) classification resulted from a five-year study 
assembled by the World Health Organization (WHO) 
and was published in 1971, being accepted as the first 
international categorization for those tumors. Since 
then, OTs grouping has been an academic exercise 
for the Oral Medicine/Oral Pathology specialty.1 The 
classifications published by the WHO reflect the current 
status of comprehension of OTs; adaptations to that 
classification as well as updates become necessary 
as clinical and scientific experiences accumulate. 
Although such publications are based on specialists’ 
opinions, they may be potentially contested by some 
pathologists. Nevertheless, it is recommended that 
all professionals employ and follow the presented 
categorization aiming at international standardization, 
given that all oral pathologists could benefit from it.2
The 1971 classification brings OTs as “Neoplasms 
and tumors related to odontogenic tissues”. Such 
edition classifies the odontogenic keratocyst under 
“Epithelial Cysts”, specifically odontogenic cysts under 
development and termed as primordial cyst or simply 
keratocyst. Nonetheless, odontogenic keratocyst 
presents a single form of developed odontogenic cyst 
and deserves special attention due to its pathological 
characteristics and specific clinical behavior.2,3 The 1992 
classification continued to include OTs as “Neoplasms 
and other tumors related to odontogenic tissues” and 
the odontogenic keratocyst still as odontogenic cysts 
under development, but its name was changed to 
odontogenic keratocyst (OK).4 The 2005 WHO edition 
defined OTs as a group of heterogenous lesions 
that could vary from hamartomatous or neoplastic 
proliferations to benign neoplasms or malignant 
tumors with metastatic potential.5 Such edition omitted 
the classification of odontogenic cysts and reclassified 
and redefined OK to keratocystic odontogenic tumor 
(KOT). 
The last published edition by the WHO outlines 
OTs as rare tumors – since these constitute only 
1% of all oral tumors –, as well as benign entities 
that somehow may present an aggressive behavior 
and high recurrence rates.6 The 2017 edition places 
odontogenic cysts back to OTs and now classifies KOT 
as a cyst, also terming it odontogenic keratocyst.6 
Considering that this is a common lesion, it is evident 
that reclassification and redefinition by this entity – 
both for tumor and cyst – causes a significant increase 
in the frequency and prevalence of OTs, as well as the 
ranking order among OTs. Other lesions that were 
included or excluded from 2017’s classification could 
also influence the OTs epidemiology, less significantly 
than OK, as they are notably rarer. For the 2017 
classification, the sclerosing odontogenic carcinoma, 
odontogenic carcinosarcoma, primordial odontogenic 
tumor and cemento-ossifying fibroma were included. 
The cystic calcifying odontogenic tumor was, relocated 
to the odontogenic cysts classification, whereas odonto 
ameloblastoma and ameloblastic fibro-odontoma were 
not considered to be single entities.
Thus, this study sought to approach the history 
of reclassifications and redefinitions around the 
odontogenic keratocyst (OK), as proposed by the WHO, 
as well as to understand the impact of those changes 
on the prevalence and epidemiology of odontogenic 
tumors (OTs) by assessing the collection of cases 
diagnosed in an Oral Pathology Service between 
January 1996 and December 2016. 
Methodology
Sample selection
After approval by the Research Ethics Committee 
under the protocol 077338/2017, every single report 
of OTs that was diagnosed between January 1996 
and December 2016 in the Oral Pathology laboratory 
of the Federal University of Alfenas (UNIFAL-MG) was 
assessed. Inclusion criteria comprised a microscopic 
final diagnosis of OT, including those in syndrome cases 
patients. There were no exclusion criteria.
Demographic data assessment 
The following demographic data of the patients 
were retrieved and analyzed: age, gender, skin 
color and OTs data: clinical aspect, symptomatology, 
radiographic, macroscopic size and clinical diagnostic 
hypotheses.
Statistical Analysis
The prevalence of OTs was established considering 
the total number of biopsies performed in the laboratory 
from 1996 to 2016. Frequency and prevalence of OTs 
from January 1996 to December 2005 was compared 
to the frequency and distribution from January 2006 
to December 2016. Statistical comparisons were made 
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applying the Chi-square test (p<0.05 considered to 
be statistically significant).
Results
Out of 7,805 cases diagnosed between the reported 
period, 200 (2.56%) were defined as OTs, being the 
prevalence before and after 2005 depicted in Table 
1. Out of 200 cases between 1996 and 2005, 41 
cases of OTs (20.5%) were found. Odontoma was the 
most frequent with 23 (56.09%) cases, followed by 
ameloblastoma with 8 (19.51%) cases, and myxoma 
with 03 (7.31%) cases.
Between 2006 and 2016, after WHO’s 2005 
reclassification, we found 159 (79.5%) cases of OTs. 
During this period the most frequent lesion was KOT 
(68; 42.76%) cases, followed by odontoma (39; 
24.52%) cases and ameloblastoma (21; 13.20%) 
cases. Of the 200 selected OTs cases, 108 (54%) 
affected males and 92 (46%) affected females, for a 
1.17:1 male:female ratio. Considering that there was 
no statistically significant difference between groups, 
OTs affected both genders equally when this sample 
was analyzed. Distribution of OTs between genders is 
shown in Table 2.
Most cases related to the mandible, being 116 
(58%) in this site (p<0.0001), which was followed by 
the maxilla with 68 (34%) cases, and 16 (8%) of those 
cases did not present this information. Distribution of 
OTs according to anatomical localization is shown in 
Table 3. Most cases are related to patients between 11 
and 20 years of age, being 76 (38%) cases in patients 
at their second decade of life (p<0.0001), followed 
by the third decade, 25 (12.5%), and fourth decade, 
                     Period 1996-2005 2006-2016
              ODONTOGENIC TUMOURS
KCOT -   (0,00%) 68 (42,76%)
Odontoma 23 (56,09%) 39 (24,52%)
Ameloblastoma 08 (19,51%) 21 (13,20%)
Myxoma 03 (7,31%) 10 (6,28%)
CCOT -   (0,00%) 11 (6,91%)
Odontogenic fibroma 01 (2,43%) 07 (4,40%)
Squamous Odontogenic Tumour 02 (4,87%) -   (0,00%)
CEOT 01 (2,43%) 01(0,62%)
Cementoblastoma 02 (4,87%) -   (0,00%)
AOT -  (0,00%) 02 (1,25%)
Odontoameloblastoma 01 (2,43%) -  (0,00%)
Total 41 (100%) 159  (100%)
Table 1- Distribution of OTs diagnosed before and after 2005 in a Brazilian Oral Pathology Center
Gender Male Female Total
ODONTOGENIC TUMOURS
KCOT 37 31 68
Odontoma 35 27 62
Ameloblastoma 16 13 29
Myxoma 6 7 13
CCOT 5 6 11
Odontogenic fibroma 3 5 8
Squamous Odontogenic Tumour - 2 2
CEOT 1 1 2
Cementoblastoma 2 - 2
AOT 2 - 2
Odontoameloblastoma 1 - 1
Total 108 92 200
Table 2- Distribution of OTs according to histology and gender in a Brazilian Oral Pathology Center
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18 (9%). Age was not disclosed in 31 (15.5%) cases. 
The distribution of OTs according to age is presented 
in Table 4.
Prevalence of OTs before WHO’s 2005 classification 
was 20.5%, whereas after the change in classification it 
grew to 79.5%, for a 287.80% increase (p<0.0001). If 
KOT had not been included after 2005, the prevalence 
of OTs from 2006 to 2016 would be of 45.5%, which 
would have been a 121.95% (p<0.05) increase.
Discussion
The objective of this study was to bring up the 
history of the reclassifications and redefinitions of 
OK proposed by the WHO, and then to establish the 
impact of such classifications in the prevalence and 
epidemiology of OTs by evaluating the diagnosed cases 
in an Oral Pathology Service between January 1996 
and December 2016.
Since the first histological definition and 
classification of OTs was established in 1966 by the 
Department of Oral Pathology of the Royal School of 
Dentistry, in Copenhagen, Denmark, the knowledge 
about these lesions has evolved continuously, and 
its classifications have been changing in parallel. 
The 1971 WHO classification contained “odontogenic 
tumors, odontogenic cysts and allied lesions”. In 
1992, such classification was titled “odontogenic 
tumors”, but still included odontogenic cysts and allied 
lesions.2 In 2005, in a third edition, “odontogenic 
tumors” remained disclosed, although some of the 
“allied lesions” remained included; however, cysts 
were now cut out despite the extreme significance 
of traditional odontogenic cysts for the differential 
diagnosis of odontogenic tumors, such as the glandular 
odontogenic cyst and cystic variants of calcifying cystic 
odontogenic tumors.7 The OK was reclassified as a 
neoplasia and the recommendation of the new term 
keratocystic odontogenic tumor (KCOT) was taken.6 In 
2017, a new classification was described and the most 
controverted decision was related to shifting KCOT 
back to the category of cyst and name it OK or OKC. 
Most OTs cases belonged to patients living their 
second decade of life – followed by the third decade 
–, corroborating the studies made by Servato (2010) 
and Jaeger, et al. (2016).8,9 There was no statistically 
significant difference between genders and the 
mandible was the most affected site, with more than 
half of the cases belonging to this site. 
The most important results of this study are 
related to the prevalence of lesions. Using the 2005 
WHO classification (3rd edition), a 287.80% increase 
Site Mandible Maxilla N.A.
ODONTOGENIC TUMOURS
KCOT 49 18 1
Odontoma 29 28 5
Ameloblastoma 25 - 4
Myxoma 4 7 2
CCOT 1 10 -
Odontogenic fibroma 4 2 2
Squamous Odontogenic Tumour 1 1 -                
CEOT 2 - -
Cementoblastoma 1 1 -
AOT - 1 1
Odontoameloblastoma - - 1
Total 116 68 16
Table 3- Distribution of OTs according to anatomical site in a Brazilian Oral Pathology Center
Age Range nº Percentage
0.0  |— 10.0 10 5,92%
11.0 |— 20.0 76 44,97%
21.0 |— 30.0 25 14,79%
31.0 |— 40.0 18 10,65%
41.0 |— 50.0 11 6,51%
51.0 |— 60.0 16 9,47%
61.0 |— 70.0 8 4,73%
71.0 |— 80.0 2 1,18%
81.0 |— 90.0 3 1,78%
91.0 |— 100.0 0 0,00%
TOTAL 169 100,00%
Table 4- Distribution of OTs according to age in a Brazilian Oral 
Pathology Center
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in the prevalence of OTs was detected, considering 
that this result corroborates some published studies 
such as a 2010 study by Gaitán-Cepeda, which also 
aimed at establishing the frequency and prevalence 
of OTs before and after 2005.10 By utilizing files from 
a Mexican Histopathology Head and Neck Service, 
the authors demonstrated that redefining OK as a 
tumor led to a 92% increase in the frequency and 
prevalence of OTs. Another study published by Servato 
in 2013 showed a 50% increase in the frequency of 
OTs after reclassifying OK as tumor.9 In 2016, another 
similar study indicated a 464.2% increase in the 
prevalence of OTs when the 3rd edition was used for 
OT reclassification.8,9,10 Despite the obvious differences 
between the obtained percentages from one study 
to another, every report demonstrated significant 
increases regarding OTs prevalence when using the 
2005 classification. In addition, our study showed that 
when using the 1992 version (2nd edition), odontoma 
was the most frequent OT; however, when applying 
the 2005 version (3rd edition), KOT became the most 
frequent OT. These data agree with similar previously 
published studies.8,9,10 One possible explanation for 
both results is the inclusion or exclusion of OK in OT. 
Probably, this is the most important cause to such 
increase in 2005, and change in the most prevalent 
lesion. 
In 2005, the most debated decision of WHO 
was the reclassification of OK as a neoplasia and 
the recommendation of the new term keratocystic 
odontogenic tumor (KCOT).6 To justify such 
reclassification, authors have emphasized the 
aggressive behavior, recurrence rate and occasional 
presence of a solid variant, as well as PTCH gene 
mutations in such lesion. Nevertheless, those 
mutations were found in syndromic patients and the 
six WHO references in non-syndromic cases included 
syndromic patients. Numerous subsequent studies 
showed PTCH mutations in approximately 85% of OKs 
in syndromic patients, against 30% in non-syndromic 
patients. However, mutations are non-clonal or limited 
to PTCH, since p16, P53, MCC, TSLC1, LTAS2 and 
FHIT mutations were also related in OKs. Although 
neoplasia is characterized by genetic aberrations, 
there are currently no unique genetic alterations to 
define neoplasia. The molecular/genetic modification 
that happens to some OKs may influence their 
biologic behavior but still not characterize the lesion 
of neoplastic rather than cystic origin. Neoplasia show 
growth autonomy and do not involute spontaneously. 
OKs, on the other hand, have been well-documented 
following regression after decompression; furthermore, 
orthokeratinized OKs and dentigerous cysts contained 
PTCH mutations as well. Cutaneous cysts in syndromic 
and non-syndromic patients are histologically identical 
to OKs but classified as cysts instead of tumors. In 
2005 (3rd edition), WHO authors chose to classify all 
ghost cell lesions as neoplasia. The solid neoplastic 
variant was suggested to be named Ghost Cell 
Dentinogenic Tumor, and the cystic variant Calcifying 
Cystic Odontogenic Tumor.11,17 
Several changes were considered and incorporated 
so a contemporary consent could provide the world 
head and neck pathology community with an infra-
structure to support the diagnoses of odontogenic 
cysts, odontogenic tumors and allied osseous tumors. 
Odontogenic cysts that were omitted from the 2005 
classification were reincorporated in 2017 (4th edition) 
and significantly updated after the 1992 classification.18 
The subdivision of benign OTs in the 2017 classification 
was changed regarding its nomenclature, which was 
justified by the authors as a simplification. Benign 
OTs were thus subdivided into odontogenic epithelium 
tumors, odontogenic epithelium, mesenchyme and 
mesenchymal tumors.6 The most controverted decision 
of 2017 regarded to shifting KOT back to the category 
of cyst and name it OK. It is worth noting that the 
WHO consent does not affirm that OKs are not of 
neoplastic origin, although it believes that there is a 
lack of support to justify OKs as tumors.11,16,18 Other 
lesions that were excluded or included with 2017 
classification could also influence the epidemiology of 
OTs, although less significantly than OK as those other 
entities are rare. In 2017, the authors unanimously 
classified the calcifying cystic odontogenic tumor 
as an odontogenic cyst, and a 2008 study analyzed 
the WHO classification about ghost cells, suggesting 
the need for complementary studies to unravel their 
biological behavior. The same authors pointed out 
that less than 90% of all ghost cell lesions are entirely 
cystic or related to odontomas, lesions that are not 
classified as tumors whatsoever.18,19 Some examples of 
the 2017 classification modification are the inclusion 
of odontogenic carcinoma, reinsertion of odontogenic 
carcinosarcoma, exclusion of odontoameloblastoma, 
the description of a new OT referred in 2014 as the 
primordial odontogenic tumor.18,20,21 Moreover, for 
the 2017 edition, the authors decided to group both 
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ameloblastic fibrodentinoma and ameloblastic fibro-
odontoma under the odontoma section. However, some 
ameloblastic fibromas do not produce hard tissues and 
may be regarded as true neoplasia once leading to 
mineralized odontogenic tissue, they probably evolve 
into odontomas and thus are classified such.18,22,23
Conclusion
We identified a significant increase (287.80%) in 
the prevalence of OTs when the 2005 (3rd edition) was 
used. Such finding corroborates with similar studies 
that were conducted previously and may be explained 
by the fact that OK was considered an OT in 2005. 
While this classification of odontogenic lesions might 
be considered as an academic exercise, the research 
process and updates involved are crucial for the correct 
diagnosis and treatment imposed. 
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